Title |
Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy
|
---|---|
Published in |
Medical Oncology, April 2014
|
DOI | 10.1007/s12032-014-0960-1 |
Pubmed ID | |
Authors |
Thomas E. Stinchcombe |
Abstract |
Squamous cell carcinoma of the lung accounts for 20-30% of non-small cell lung cancers (NSCLC). Despite the differences in disease characteristics between squamous and non-squamous NSCLC, both have historically been treated similarly in the clinic. Recently approved drugs have revealed differences in activity and safety profiles across histologic subtypes and have applicability in treating non-squamous, but not typically squamous, NSCLC. Exploration of immune checkpoints--co-inhibitory molecules used to regulate immune responses--has resulted in novel immunotherapies designed to interrupt signaling through the cytotoxic T lymphocyte-associated antigen-4 or programmed cell death protein-1 pathways on lymphocytes. Modulation of these pathways can lead to restored antitumor immune responses, and preliminary evidence shows that agents targeting these pathways have activity in lung cancer, including squamous NSCLC. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 35 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 17% |
Other | 4 | 11% |
Researcher | 4 | 11% |
Student > Master | 4 | 11% |
Student > Doctoral Student | 3 | 9% |
Other | 7 | 20% |
Unknown | 7 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 49% |
Nursing and Health Professions | 3 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Immunology and Microbiology | 2 | 6% |
Agricultural and Biological Sciences | 1 | 3% |
Other | 3 | 9% |
Unknown | 7 | 20% |